BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsFDA / regulatory

Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to $3 billion CHICAGO --(BUSINESS WIRE)--Sep.

Related news

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

SUPNSupernus2026-10-21 23:45 EST

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

TEVATeva Pharmaceutical Industries2026-08-28 10:17 EST

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

DNLIDenali Therapeutics2026-10-30 13:30 EST

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

CGTXCognition Therapeutics2026-10-22 10:00 EST

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

CLNNClene Inc.2026-10-19 12:00 EST

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

CGTXCognition Therapeutics2026-09-29 11:30 EST

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

JNJJohnson & Johnson2026-09-21 14:33 EST

European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

View all latest news

Xeris Pharmaceuticals

Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome....

Recent company news

XERSXeris Pharmaceuticals2026-11-05 12:00 EST

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

XERSXeris Pharmaceuticals2026-11-02 13:00 EST

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

XERSXeris Pharmaceuticals2026-10-15 12:00 EST

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

XERSXeris Pharmaceuticals2026-10-02 21:00 EST

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Stock data

Close
13.08 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States